Physician profile
David W Lowe
NPI 1770536062
$18,176.85
in general payments reported to CMS, 2019-2025
22 companies · $344 in 2025
The $344 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $2,131 · 2021: $1,579 · 2022: $310 · 2023: $124 · 2024: $106 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $514 · Education: $34.00 · Consulting Fee: $26.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $513.66 |
| Education | $34.00 |
| Consulting Fee | $26.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $17,017.33 | 2019-2024 | Spiriva Respimat, Ofev |
| Philips North America LLC | $156.77 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $124.12 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Amgen INC. | $120.43 | 2022-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $107.23 | 2019-2025 | Dupixent |
| Genzyme Corporation | $82.06 | 2019-2025 | |
| Electromed, INC. | $71.77 | 2019-2025 | Smartvest |
| Mylan Specialty L.P. | $52.13 | 2021-2023 | Yupelri |
| Csl Behring | $52.08 | 2020-2025 | Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $51.55 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $48.86 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $47.03 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $46.83 | 2019-2025 | |
| Glaxosmithkline, LLC. | $35.95 | 2020-2025 | Nucala |
| Alkermes, INC. | $28.53 | 2024-2025 | Vivitrol |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adma Biomanufacturing LLC | $26.15 | 2025 | |
| Hospira, INC. | $24.59 | 2022 | |
| Grifols USA, LLC | $23.81 | 2019-2023 | Prolastin-C Liquid |
| Advanced Respiratory, INC | $19.98 | 2019 | |
| Endo Pharmaceuticals INC. | $14.89 | 2019 | |
| Biocryst US Sales Co., LLC | $12.92 | 2023 | Orladeyo |
| Itamar Medical INC | $11.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.